Genzyme's John Butler sparks Inspiration as CEO
This article was originally published in Scrip
Inspiration Biopharmaceuticals, a biopharmaceutical company focused on finding new treatments for haemophilia, has appointed John Butler CEO, replacing Dr Michael Griffith, who has taken the role of chief scientific officer and retains the title of president. Mr Butler joins Inspiration from Genzyme Corporation, where he most recently served as president of the company's rare genetic diseases business.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.